Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Cited In for PubMed (Select 17919718)

1.

Past and future of prophylactic ablation of the cervical squamocolumnar junction.

Franceschi S.

Ecancermedicalscience. 2015 Apr 29;9:527. doi: 10.3332/ecancer.2015.527. eCollection 2015.

2.

HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs.

Campari C, Fedato C, Petrelli A, Zorzi M, Cogo C, Caprioglio A, Gallo F, Giordano L, Domenighini S, Pasquale L, Prandi S, Zappa M, Giorgi Rossi P; GISCi Migrant Working Group.

Infect Agent Cancer. 2015 May 7;10:14. doi: 10.1186/s13027-015-0009-x. eCollection 2015.

3.

Major clinical research advances in gynecologic cancer in 2014.

Suh DH, Lee KH, Kim K, Kang S, Kim JW.

J Gynecol Oncol. 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. Review.

4.

Clinical significance of HPV-DNA testing for precancerous cervical lesions.

Moarcăs M, Georgescu IC, Brătilă E, Badea M, Cîrstoiu M.

J Med Life. 2014;7 Spec No. 3:37-9.

5.

Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia.

Park IU, Wojtal N, Silverberg MJ, Bauer HM, Hurley LB, Manos MM.

PLoS One. 2015 Mar 20;10(3):e0118938. doi: 10.1371/journal.pone.0118938. eCollection 2015.

6.

Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter.

Giorgi Rossi P, Fortunato C, Barbarino P, Boveri S, Caroli S, Del Mistro A, Ferro A, Giammaria C, Manfredi M, Moretto T, Pasquini A, Sideri M, Tufi MC, Cogo C, Altobelli E; HPV Self-sampling Italian Working Group.

Br J Cancer. 2015 Feb 17;112(4):667-75. doi: 10.1038/bjc.2015.11. Epub 2015 Jan 29.

PMID:
25633037
7.

A survey of population-based utility scores for cervical cancer prevention.

Simonella L, Howard K, Canfell K.

BMC Res Notes. 2014 Dec 11;7:899. doi: 10.1186/1756-0500-7-899.

8.

Immunoprevention of human papillomavirus-associated malignancies.

Wang JW, Hung CF, Huh WK, Trimble CL, Roden RB.

Cancer Prev Res (Phila). 2015 Feb;8(2):95-104. doi: 10.1158/1940-6207.CAPR-14-0311. Epub 2014 Dec 8.

PMID:
25488410
9.

Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing.

Porras C, Hildesheim A, González P, Schiffman M, Rodríguez AC, Wacholder S, Jiménez S, Quint W, Guillen D, Kreimer AR, Herrero R; CVT Vaccine Group.

J Natl Cancer Inst. 2014 Dec 5;107(1):400. doi: 10.1093/jnci/dju400. Print 2015 Jan.

PMID:
25479804
10.

High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology.

Musa J, Achenbach C, Taiwo B, Berzins B, Silas O, Daru PH, Agbaji O, Imade G, Sagay AS, Idoko JA, Kanki PJ, Murphy RL.

Infect Agent Cancer. 2014 Nov 3;9(1):36. doi: 10.1186/1750-9378-9-36. eCollection 2014.

11.

Importance of HPV Genotyping for the Screening, Therapy and Management of Cervical Neoplasias.

Jentschke M, Soergel P, Hillemanns P.

Geburtshilfe Frauenheilkd. 2012 Jun;72(6):507-512.

12.

Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M.

J Clin Microbiol. 2014 Nov;52(11):3996-4002. doi: 10.1128/JCM.01962-14. Epub 2014 Sep 10.

13.

The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies.

Guo Y, You K, Geng L, Qiao J.

J Gynecol Oncol. 2014 Oct;25(4):287-92. doi: 10.3802/jgo.2014.25.4.287. Epub 2014 Jun 18.

14.

Protecting the underscreened women in developed countries: the value of HPV test.

Ibáñez R, Autonell J, Sardà M, Crespo N, Pique P, Pascual A, Martí C, Fibla M, Gutiérrez C, Lloveras B, Moreno-Crespi J, Torrent A, Baixeras N, Alejo M, Bosch FX, de Sanjosé S.

BMC Cancer. 2014 Aug 8;14:574. doi: 10.1186/1471-2407-14-574.

15.

High-risk HPV nucleic acid detection kit-the careHPV test -a new detection method for screening.

Ying H, Jing F, Fanghui Z, Youlin Q, Yali H.

Sci Rep. 2014 Apr 16;4:4704. doi: 10.1038/srep04704.

16.

A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women.

Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, Gajda M, Hoyer H, Runnebaum IB, Dürst M.

PLoS One. 2014 Mar 19;9(3):e91905. doi: 10.1371/journal.pone.0091905. eCollection 2014.

17.

The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs.

Giorgi Rossi P, Baldacchini F, Ronco G.

Front Oncol. 2014 Feb 10;4:20. doi: 10.3389/fonc.2014.00020. eCollection 2014. Review.

18.

Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.

Uijterwaal MH, Witte BI, Van Kemenade FJ, Rijkaart D, Ridder R, Berkhof J, Balfoort-van der Meij GA, Bleeker MC, Snijders PJ, Meijer CJ.

Br J Cancer. 2014 Mar 18;110(6):1579-86. doi: 10.1038/bjc.2014.34. Epub 2014 Feb 11.

19.

Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.

Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.

PLoS One. 2014 Feb 5;9(2):e88323. doi: 10.1371/journal.pone.0088323. eCollection 2014.

20.

Detection of cervical cancer biomarker patterns in blood plasma and urine by differential scanning calorimetry and mass spectrometry.

Garbett NC, Merchant ML, Helm CW, Jenson AB, Klein JB, Chaires JB.

PLoS One. 2014 Jan 8;9(1):e84710. doi: 10.1371/journal.pone.0084710. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk